Kimera Labs, Inc.

A Biotechnology Company

Kimera Labs is an FDA registered tissue bank located in Miramar, Florida.


Company Overview

Kimera Labs Inc. is a biotechnology laboratory that develops perinatal exosome products for research and therapeutic purposes.  Since 2012, Kimera Labs and Kimera Society have invested significant resources into exosome isolation protocols for the field of regenerative medicine.  


Functioning within a 6,000 sq ft GMP facility in Miramar, Florida, we feature ISO 5 hoods, class 7 cleanrooms, in-house particle size characterization via NanoSight and flow cytometry characterization of incoming and outgoing cell phenotypes and much more.  Our products are validated and characterized via protein and nucleic acid characterization.


As a regenerative medicine focused biotechnology company founded by a  published scientist,  Kimera Labs develops therapies that harness the power of stem cells, without the use of the cells themselves. By providing regenerative cellular signals under the control of messenger and micro RNA, we believe it is possible to instantiate healing processes that can benefit patients of any age.


Letter From Our Founder



In 2002, my Oceanographer father and I were faced with an almost impossible decision. The chemotherapy we were using to treat his leukemia was no longer functional, and we were forced to choose an immunological approach, bone marrow stem cell transplantation (BMT), for which the rate of survival was 50%. We hesitated for so long that when we finally decided on BMT he was no longer eligible. I clearly remember meekly, and humiliatingly,  offering a well known transplant expert, Dr. Karen Ballen at Massachusetts General Hospital, a paper on Copper supplementation for the treatment of AML. She politely thanked me and raised her hand in a negative response. After this encounter, and two years before his death, I enrolled in the Ph.D. program at the University of Miami. I obtained an 8 year dual education in the departments of biochemistry and immunology and I am today still trying to control disease using immunological molecular approaches. One of the directions that showed early promise in chronic GVHD after BMT was the use of mesenchymal stromal cells to suppress rejection. My study of immunological manipulation, in concert with the understanding I developed in 2014 of what the 'paracrine effect' of cell communication really means (exosomes), has led our company down a path that has resulted in multiple FDA IND applications in process, and our position as one of the most well respected groups in exosome science.


I am happy to contribute to the body of knowledge of exosome research.  Feel free to ask us for our protein, mRNA, or miRNA research results that help us define the evolving science that is cellular signalling.




Duncan Ross Ph.D.

Kimera Labs is an FDA registered tissue bank located in Miramar, Florida.  Kimera Labs Amnio2 amniotic fluid product falls under 361 tissue product regulation. Kimera Labs XoGlo™ exosome product is for topical use only.


The donor mother's serum in each case is tested for the following viruses:

  • HIV
  • HTLV
  • Hepatitis B
  • Hepatitis C
  • Syphilis
  • CMV